Tags

Type your tag names separated by a space and hit enter

Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation.
Eur J Public Health. 2008 Jun; 18(3):275-82.EJ

Abstract

BACKGROUND

In accordance with World Health Organization recommendations, many European countries have introduced universal hepatitis B vaccination policies. The UK and Ireland are exceptions. In this study, we conducted an economic evaluation of a universal infant hepatitis B vaccination programme, using a six-component vaccine, compared with the current selective strategy of vaccinating high-risk infants with a monovalent hepatitis B vaccine.

METHODS

A cost effectiveness analysis was conducted using a Markov model. The perspective of the analysis was the Irish Health Service Executive. Unit cost and resource utilization data were derived from expert clinical opinion, published sources, diagnosis-related group costs for hospital admissions and local cost estimates for medical fees and laboratory investigations. A full probabilistic sensitivity analysis was undertaken. Both costs and outcomes were modelled over a period of 80 years and discounted at 3.5%.

RESULTS

Assuming an incidence of acute hepatitis B virus (HBV) infection in Ireland of 8.4 per 100,000 population, the incremental cost effectiveness ratio ranged from euro10,992/life years gained (LYG) to euro67 200/LYG, at the lowest and highest price estimates for the six-component vaccine, respectively. The cost effectiveness of universal versus selective hepatitis B vaccination was sensitive to the risk of acute HBV infection, the cost of the universal infant vaccination programme and the discount rate.

CONCLUSION

At a cost of euro29.00 per dose of the six-component vaccine, universal infant hepatitis B vaccination is cost effective at euro37 018/LYG. This compares favourably with other preventive programmes in Ireland.

Authors+Show Affiliations

National Centre for Pharmacoeconomics, St James's University Teaching Hospital, James's St, Dublin 8, Ireland. ltilson@stjames.ieNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18160389

Citation

Tilson, Lesley, et al. "Cost Effectiveness of Hepatitis B Vaccination Strategies in Ireland: an Economic Evaluation." European Journal of Public Health, vol. 18, no. 3, 2008, pp. 275-82.
Tilson L, Thornton L, O'Flanagan D, et al. Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation. Eur J Public Health. 2008;18(3):275-82.
Tilson, L., Thornton, L., O'Flanagan, D., Johnson, H., & Barry, M. (2008). Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation. European Journal of Public Health, 18(3), 275-82.
Tilson L, et al. Cost Effectiveness of Hepatitis B Vaccination Strategies in Ireland: an Economic Evaluation. Eur J Public Health. 2008;18(3):275-82. PubMed PMID: 18160389.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation. AU - Tilson,Lesley, AU - Thornton,Lelia, AU - O'Flanagan,Darina, AU - Johnson,Howard, AU - Barry,Michael, Y1 - 2007/12/26/ PY - 2007/12/28/pubmed PY - 2008/9/3/medline PY - 2007/12/28/entrez SP - 275 EP - 82 JF - European journal of public health JO - Eur J Public Health VL - 18 IS - 3 N2 - BACKGROUND: In accordance with World Health Organization recommendations, many European countries have introduced universal hepatitis B vaccination policies. The UK and Ireland are exceptions. In this study, we conducted an economic evaluation of a universal infant hepatitis B vaccination programme, using a six-component vaccine, compared with the current selective strategy of vaccinating high-risk infants with a monovalent hepatitis B vaccine. METHODS: A cost effectiveness analysis was conducted using a Markov model. The perspective of the analysis was the Irish Health Service Executive. Unit cost and resource utilization data were derived from expert clinical opinion, published sources, diagnosis-related group costs for hospital admissions and local cost estimates for medical fees and laboratory investigations. A full probabilistic sensitivity analysis was undertaken. Both costs and outcomes were modelled over a period of 80 years and discounted at 3.5%. RESULTS: Assuming an incidence of acute hepatitis B virus (HBV) infection in Ireland of 8.4 per 100,000 population, the incremental cost effectiveness ratio ranged from euro10,992/life years gained (LYG) to euro67 200/LYG, at the lowest and highest price estimates for the six-component vaccine, respectively. The cost effectiveness of universal versus selective hepatitis B vaccination was sensitive to the risk of acute HBV infection, the cost of the universal infant vaccination programme and the discount rate. CONCLUSION: At a cost of euro29.00 per dose of the six-component vaccine, universal infant hepatitis B vaccination is cost effective at euro37 018/LYG. This compares favourably with other preventive programmes in Ireland. SN - 1464-360X UR - https://www.unboundmedicine.com/medline/citation/18160389/Cost_effectiveness_of_hepatitis_B_vaccination_strategies_in_Ireland:_an_economic_evaluation_ L2 - https://academic.oup.com/eurpub/article-lookup/doi/10.1093/eurpub/ckm123 DB - PRIME DP - Unbound Medicine ER -